Skip to content
AnalystLens

Royalty Pharma 8-K Report, Financial Results (Jan 8, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed January 8, 2024
Period End
January 8, 2024
Security
RPRX
In the record · 2020–202610-K610-Q208-K80

RPRX filed 6 annual reports (10-K), 20 quarterly reports (10-Q) and 80 current reports (8-K) between 2020 and 2026.

  1. Material agreement8-K · Jul ’21Jul ’21
  2. Impairment8-K · Dec ’22Dec ’22
  3. Material agreement8-K · May ’26May ’26

01—Abstract

Summary

Summary of the 8-K filed January 8, 2024. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc (Nasdaq: RPRX) furnished an 8-K on January 8, 2024 disclosing a preliminary, unaudited update on its fiscal 2023 results, issued via a press release (Exhibit 99.1) ahead of the 42nd Annual J.P.

Morgan Healthcare Conference. The company expects full-year 2023 Portfolio Receipts of approximately $3,050 milliona, which includes a $50 million payment related to oral zavegepant and exceeds the upper end of its previous guidance range of $2,950 million to $3,000 million. Management cites underlying growth of 11% year-over-year before Biohaven-related payments, and expects Net cash provided by operating activities of approximately $2,980 million to $2,990 million for 2023.

The release also highlights capital deployment: announced transactions of approximately $13 billionb since 2020, including $4.0 billion in 2023, and $775 million of synthetic royalty transactions in 2023, the company's strongest year for that category. Management states that investments made since 2020 are estimated to add approximately $1.2 billion to Portfolio Receipts in 2025 based on consensus sales forecasts. The company also reiterated a capital deployment target of $10 billion to $12 billion for 2022 through 2026.

The company is renaming its Royalty Receipts metric as Portfolio Receipts, which it says yields the same total as the former Adjusted Cash Receipts while presenting royalty receipts net of legacy non-controlling interests. Because the figures are preliminary and unaudited, they remain subject to change pending final adjustments and audit, and a full fourth-quarter and full-year 2023 results conference call is expected in February 2024.

02—Key points

Key Highlights

  1. Preliminary 2023 Portfolio Receipts expected at approximately $3,050 million, above the previous guidance range of $2,950 million to $3,000 million and including a $50 million payment related to oral zavegepant.
  2. Underlying growth of 11% year-over-year prior to Biohaven-related payments, described as the third consecutive year of double-digit underlying growth since the 2020 IPO.
  3. Net cash provided by operating activities expected at approximately $2,980 million to $2,990 million for full-year 2023.
  4. Announced transactions of $4.0 billion in 2023 and approximately $13 billion since 2020; synthetic royalty transactions of $775 million in 2023, the strongest year on record for that category.
  5. Investments since 2020 are estimated to add approximately $1.2 billion to Portfolio Receipts in 2025, based on consensus sales forecasts.
  6. Capital deployment target of $10 billion to $12 billion from 2022 to 2026, with a potential longer-term average of $4 billion to $5 billion per year.
  7. Portfolio Receipts replaces the Adjusted Cash Receipts label, with the same total but royalty receipts now reported net of legacy non-controlling interests; figures remain preliminary and unaudited.

03—Questions

Frequently Asked Questions

  1. What did Royalty Pharma report for full-year 2023 Portfolio Receipts?

    The company expects Portfolio Receipts of approximately $3,050 million for full-year 2023, which includes a $50 million payment related to oral zavegepant and exceeds the upper end of its prior guidance range of $2,950 million to $3,000 million.

  2. What is the expected 2023 operating cash flow?

    Royalty Pharma expects Net cash provided by operating activities of approximately $2,980 million to $2,990 million for full-year 2023.

  3. Why did the company change the name of Adjusted Cash Receipts?

    The company renamed the metric Portfolio Receipts to increase transparency into the economics of individual royalties, since royalty receipts by product and franchise will now be reported net of legacy non-controlling interests. The total under the new name equals the prior Adjusted Cash Receipts total.

  4. How much capital did Royalty Pharma deploy and what is its outlook?

    The company announced transactions of $4.0 billion in 2023 and approximately $13 billion since 2020. It has a capital deployment target of $10 billion to $12 billion from 2022 to 2026 and believes it could over time double its average annual deployment to $4 billion to $5 billion.

  5. Are these 2023 figures final?

    No. The results are preliminary and unaudited and remain subject to change pending the completion of final adjustments and the audit of financial statements. Management plans a conference call to discuss full fourth-quarter and full-year 2023 results in February 2024.

04—Continue

← View all 8-K filings